Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LAB

Standard BioTools Inc

Feb 11 • 04:00PM ET

1.19

-0.05 -4.03 %

Healthcare • Medical Devices • USA • NASD

Peers: TMO DHR A ILMN BIO QGEN TECH TWST PACB DNA

| Held by: VTI IWM VXF ARKG IBB IWN VTWO SCHA IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	4.15%	Shs Outstand	383.61M	Perf Week	-7.03%
Market Cap	457.63M	Forward P/E	-	EPS next Y	-0.12	Insider Trans	390.88%	Shs Float	368.61M	Perf Month	-21.19%
Enterprise Value	290.12M	PEG	-	EPS next Q	-0.05	Inst Own	76.07%	Short Float	2.66%	Perf Quarter	1.71%
Income	-128.25M	P/S	3.55	EPS this Y	60.16%	Inst Trans	-1.56%	Short Ratio	5.90	Perf Half Y	-9.16%
Sales	128.83M	P/B	1.14	EPS next Y	42.98%	ROA	-17.93%	Short Interest	9.79M	Perf YTD	-7.03%
Book/sh	1.04	P/C	2.35	EPS next 5Y	42.89%	ROE	-24.63%	52W High	1.72 -30.81%	Perf Year	-8.81%
Cash/sh	0.51	P/FCF	-	EPS past 3/5Y	12.51% 11.61%	ROIC	-30.40%	52W Low	0.92 29.35%	Perf 3Y	-41.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.13% 8.27%	Gross Margin	46.52%	Volatility	4.50% 5.97%	Perf 5Y	-78.75%
Dividend TTM	-	EV/Sales	2.25	EPS Y/Y TTM	52.28%	Oper. Margin	-83.21%	ATR (14)	0.08	Perf 10Y	-80.23%
Dividend Ex-Date	-	Quick Ratio	4.14	Sales Y/Y TTM	-17.37%	Profit Margin	-99.55%	RSI (14)	31.91	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	4.38	EPS Q/Q	-24.97%	SMA20	-16.55%	Beta	1.34	Target Price	1.55
Payout	-	Debt/Eq	0.07	Sales Q/Q	-56.52%	SMA50	-17.37%	Rel Volume	1.24	Prev Close	1.24
Employees	818	LT Debt/Eq	0.06	Earnings	Feb 24 AMC	SMA200	-7.67%	Avg Volume	1.66M	Price	1.19
IPO	Feb 10, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	-107.85% 8.62%	Trades		Volume	2,064,433	Change	-4.03%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Downgrade	TD Cowen	Buy → Hold	$1.55
Feb-27-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

Feb-10-26 07:00AM	Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
Jan-30-26 09:09AM	Standard BioTools Completes Sale of SomaLogic to Illumina (GlobeNewswire)
Jan-08-26 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue (GlobeNewswire) +20.31%
Nov-19-25 11:30AM	Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry (Business Wire)
Nov-10-25 12:15PM	Illumina Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks (PR Newswire)
05:31PM	Loading…
Nov-04-25 05:31PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 08:01AM	Earnings To Watch: Standard BioTools Inc (LAB) Reports Q3 2025 Result (GuruFocus.com)
Oct-21-25 07:00AM	Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025 (GlobeNewswire)
Sep-03-25 09:15AM	Illumina Protein Prep launches to drive greater proteomic insights for improved drug discovery and development (PR Newswire)
Aug-11-25 07:00PM	Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:09PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-08-25 09:25AM	What to Expect from Standard BioTools Inc (LAB) Q2 2025 Earnings (GuruFocus.com)
Aug-07-25 05:30PM	Doximity (DOCS) Q1 Earnings and Revenues Top Estimates (Zacks)
07:00AM	Loading…
Aug-06-25 07:00AM	Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study (GlobeNewswire)
Jul-21-25 07:00AM	Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025 (GlobeNewswire)
Jun-26-25 08:07AM	Illumina Stock May Benefit From New Agreement to Acquire SomaLogic (Zacks)
Jun-25-25 12:16AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire)
Jun-23-25 07:13AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire) +17.14%
07:05AM	Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina (GlobeNewswire)
06:58AM	Illumina to buy SomaLogic for up to $425M (MedTech Dive)
May-30-25 07:00AM	Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series (GlobeNewswire)
May-09-25 05:00PM	Labrador Gold Announces Resignation of Director Kai Hoffmann (GlobeNewswire) +8.41%
May-07-25 08:26AM	Q1 2025 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
03:20AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-06-25 05:15PM	Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.83%
04:01PM	Standard BioTools Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 10:10AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-24-25 07:00AM	Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 (GlobeNewswire)
04:05PM	Loading…
Apr-22-25 04:05PM	Sight Sciences Appoints Gary Burbach to its Board of Directors (GlobeNewswire) +6.72%
07:00AM	Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 (GlobeNewswire)
Feb-27-25 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.68%
07:09AM	Q4 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
02:22AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Feb-26-25 06:52PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance) -7.14%
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 10:54AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.26%
Feb-12-25 07:00AM	Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 (GlobeNewswire)
Jan-13-25 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue (GlobeNewswire) +26.38%
Jan-08-25 07:00AM	Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine (GlobeNewswire)
Dec-19-24 08:00AM	Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 08:00AM	Standard BioTools Appoints Alex Kim as Chief Financial Officer (GlobeNewswire)
Oct-31-24 11:00AM	Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ... (GuruFocus.com)
08:01AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 05:20PM	Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.43%
04:15PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-21-24 09:03PM	Millennium Management LLC Acquires Shares in Standard BioTools Inc (GuruFocus.com)
Oct-16-24 08:00AM	Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 (GlobeNewswire)
Oct-03-24 04:56AM	Is Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-24-24 08:00AM	Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan 11K Platform (GlobeNewswire) +5.35%
Sep-18-24 08:00AM	Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) (GlobeNewswire)
Aug-26-24 08:00AM	Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-23-24 06:03PM	Appian, Bitfarms, Standard BioTools, and More Stocks See Action From Activist Investors (Barrons.com) +9.74%
Aug-06-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 09:14AM	Q2 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -36.61%
Jul-31-24 09:57PM	LAB Stock Earnings: Standard BioTools Reported Results for Q2 2024 (InvestorPlace)
05:40PM	Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Standard BioTools Announces Senior Leadership Changes (GlobeNewswire)
04:01PM	Standard BioTools Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-17-24 08:01AM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024 (GlobeNewswire)
May-28-24 04:01PM	Standard BioTools Purchases the Carterra LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers (GlobeNewswire)
May-22-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-24 08:00AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 10:45AM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 08:59PM	LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024 (InvestorPlace) -5.49% +7.59%
04:33PM	Standard BioTools: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%
Jan-05-24 08:46AM	Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools (GlobeNewswire)
Jan-04-24 10:23PM	Standard BioTools Stockholders Approve Merger with SomaLogic (GlobeNewswire) -5.39%
09:44PM	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting (PR Newswire)
Dec-29-23 05:04PM	Glass Lewis Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-28-23 04:16PM	Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools (PR Newswire) +5.45%
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire) +7.54%
Dec-22-23 06:57PM	ISS Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-21-23 08:00AM	SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools (GlobeNewswire)
Dec-20-23 09:00AM	Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools (GlobeNewswire) -8.10%
Dec-17-23 03:37PM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-12-23 04:32PM	SomaLogic Shareholder Madryn Opposes Standard BioTools Merger (Bloomberg)
Dec-11-23 10:37AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-06-23 11:18AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-04-23 08:00AM	Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger (GlobeNewswire)

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Casdin Partners Master Fund, L	Director	Dec 04 '25	Buy	1.45	150,000	217,020	72,100,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Dec 02 '25	Buy	1.42	125,000	177,512	71,875,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Dec 03 '25	Buy	1.44	75,000	108,037	71,950,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Nov 25 '25	Buy	1.30	7,550,000	9,838,405	71,750,000	Nov 26 04:58 PM
Casdin Partners Master Fund, L	Director	Nov 24 '25	Buy	1.43	150,000	214,875	64,200,000	Nov 26 04:58 PM
Casdin Partners Master Fund, L	Director	Nov 20 '25	Buy	1.30	450,000	586,260	64,050,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 19 '25	Buy	1.28	350,000	448,910	63,600,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 18 '25	Buy	1.23	275,000	339,405	63,250,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 13 '25	Buy	1.20	450,000	541,395	62,500,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 14 '25	Buy	1.24	250,000	309,800	62,750,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 17 '25	Buy	1.22	225,000	275,580	62,975,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 12 '25	Buy	1.19	375,000	445,838	62,050,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 11 '25	Buy	1.20	300,000	358,800	61,675,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 10 '25	Buy	1.17	275,000	321,915	61,375,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 07 '25	Buy	1.12	225,000	252,765	61,100,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Sep 09 '25	Buy	1.29	100,000	128,920	60,875,000	Sep 11 09:03 PM
Casdin Partners Master Fund, L	Director	Sep 04 '25	Buy	1.28	250,000	319,350	60,775,000	Sep 05 07:08 PM
Casdin Partners Master Fund, L	Director	Sep 03 '25	Buy	1.27	250,000	316,400	60,525,000	Sep 05 07:08 PM
Casdin Partners Master Fund, L	Director	Aug 22 '25	Buy	1.26	200,000	252,680	59,950,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 25 '25	Buy	1.24	200,000	248,180	60,150,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 26 '25	Buy	1.26	125,000	157,938	60,275,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 15 '25	Buy	1.22	150,000	183,210	59,750,000	Aug 15 09:18 PM
Casdin Partners Master Fund, L	Director	Aug 14 '25	Buy	1.21	133,220	161,543	59,600,000	Aug 15 09:18 PM
Casdin Partners Master Fund, L	Director	Aug 13 '25	Buy	1.31	75,000	98,280	59,466,780	Aug 15 09:18 PM
Kim Hanjoon Alex	Chief Financial Officer	May 23 '25	Sale	0.94	1,428	1,344	930,286	May 28 05:54 PM
Mackay Sean	SVP & Chief Business Officer	May 23 '25	Sale	0.94	13,217	12,437	843,076	May 28 05:52 PM
Egholm Michael	President & CEO	May 23 '25	Sale	0.94	5,473	5,150	2,741,191	May 28 05:44 PM
Kim Hanjoon Alex	Chief Financial Officer	May 22 '25	Sale	1.00	1,355	1,358	931,714	May 27 08:33 PM
Egholm Michael	President & CEO	May 22 '25	Sale	1.00	5,116	5,126	2,746,664	May 27 08:28 PM
Mackay Sean	SVP & Chief Business Officer	May 21 '25	Sale	1.03	12,838	13,223	868,829	May 23 06:13 PM
Mackay Sean	SVP & Chief Business Officer	May 22 '25	Sale	1.00	12,536	12,561	856,293	May 23 06:13 PM
Mackay Sean	Officer	May 23 '25	Proposed Sale	0.94	13,217	12,441		May 23 04:19 PM
Kim Hanjoon Alex	Officer	May 23 '25	Proposed Sale	0.94	1,428	1,344		May 23 04:18 PM
Egholm Michael	Officer	May 23 '25	Proposed Sale	0.94	5,473	5,152		May 23 04:09 PM
Egholm Michael	President & CEO	May 21 '25	Sale	1.03	4,719	4,861	2,751,780	May 22 08:03 PM
Kim Hanjoon Alex	Chief Financial Officer	May 21 '25	Sale	1.03	1,407	1,449	933,069	May 22 08:01 PM
Egholm Michael	Officer	May 22 '25	Proposed Sale	1.00	5,116	5,126		May 22 04:20 PM
Mackay Sean	Officer	May 22 '25	Proposed Sale	1.00	12,536	12,560		May 22 04:13 PM
Kim Hanjoon Alex	Officer	May 22 '25	Proposed Sale	1.00	1,355	1,358		May 22 04:07 PM
Kim Hanjoon Alex	Officer	May 21 '25	Proposed Sale	1.03	1,407	1,451		May 21 04:22 PM
Mackay Sean	Officer	May 21 '25	Proposed Sale	1.03	12,838	13,240		May 21 04:16 PM
Egholm Michael	Officer	May 21 '25	Proposed Sale	1.03	4,719	4,867		May 21 04:13 PM
Egholm Michael	President & CEO	Apr 04 '25	Option Exercise	0.00	196,512	0	2,832,518	Apr 08 04:04 PM
Kim Hanjoon Alex	Chief Financial Officer	Apr 04 '25	Option Exercise	0.00	70,183	0	962,281	Apr 08 04:03 PM
Casdin Partners Master Fund, L	Director	Feb 28 '25	Buy	1.06	4,820,959	5,134,321	58,846,780	Mar 04 08:19 PM

Open in Screener

TVTX

Travere Therapeutics Inc

Feb 11 • 04:00PM ET

30.22

-0.10 -0.33 %

Healthcare • Biotechnology • USA • NASD

TVTX Travere Therapeutics Inc daily Stock Chart

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT PJP

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	2.05%	Shs Outstand	89.46M	Perf Week	-4.61%
Market Cap	2.70B	Forward P/E	35.26	EPS next Y	0.86	Insider Trans	-23.37%	Shs Float	87.64M	Perf Month	-11.38%
Enterprise Value	2.78B	PEG	-	EPS next Q	0.00	Inst Own	116.78%	Short Float	16.54%	Perf Quarter	-12.10%
Income	-88.54M	P/S	6.20	EPS this Y	91.78%	Inst Trans	2.11%	Short Ratio	6.96	Perf Half Y	73.58%
Sales	435.83M	P/B	36.75	EPS next Y	355.59%	ROA	-16.98%	Short Interest	14.49M	Perf YTD	-20.91%
Book/sh	0.82	P/C	10.62	EPS next 5Y	-	ROE	-410.78%	52W High	42.13 -28.27%	Perf Year	27.24%
Cash/sh	2.84	P/FCF	-	EPS past 3/5Y	-10.63% -3.34%	ROIC	-22.27%	52W Low	12.91 134.08%	Perf 3Y	47.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.83% 5.87%	Gross Margin	85.08%	Volatility	5.86% 6.67%	Perf 5Y	8.74%
Dividend TTM	-	EV/Sales	6.38	EPS Y/Y TTM	77.02%	Oper. Margin	-20.59%	ATR (14)	1.87	Perf 10Y	116.32%
Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	114.22%	Profit Margin	-20.32%	RSI (14)	44.08	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	2.75	EPS Q/Q	135.55%	SMA20	0.52%	Beta	0.81	Target Price	42.29
Payout	-	Debt/Eq	4.48	Sales Q/Q	162.11%	SMA50	-9.62%	Rel Volume	0.52	Prev Close	30.32
Employees	385	LT Debt/Eq	4.40	Earnings	Oct 30 AMC	SMA200	22.97%	Avg Volume	2.08M	Price	30.22
IPO	Oct 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	192.20% 56.70%	Trades		Volume	1,089,913	Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Reiterated	Citigroup	Buy	$34 → $48
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22

Show Previous Ratings

Feb-11-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-04-26 04:30PM	Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit (Business Wire) -6.98%
Jan-28-26 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.65%
Jan-22-26 09:52PM	BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari (Insider Monkey) +5.24%
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
10:54AM	Loading…
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
06:44AM	Travere Stock Slips After FDA Delays Review Of Key Kidney Drug (Benzinga)
Jan-13-26 07:51PM	Why Travere Therapeutics Stock Got Trounced on Tuesday (Motley Fool) -14.63%
04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily)
04:35PM	Stocks Fall on Weakness in Software and Credit Card Companies (Barchart)
01:24PM	Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire)
11:19AM	Options Bears Eye Plummeting Biotech Stock (Schaeffer's Research)
11:17AM	Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat (Barchart)
09:54AM	Travere Therapeutics Hammered On A Potential, Surprise Delay For Filspari (Investor's Business Daily)
Jan-12-26 05:00PM	Travere Therapeutics Provides Corporate Update and 2026 Outlook (Business Wire)
04:30PM	Loading…
Jan-05-26 04:30PM	Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -6.06%
Dec-25-25 10:44AM	Dow Jones, S&P 500 Hit Record Highs. Stock Market Closed For Christmas. (Investor's Business Daily)
Dec-24-25 06:51PM	Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday (Motley Fool) +13.91%
04:40PM	Nvidia Buying AI Chip Startup Groq In Record $20 Billion Deal: CNBC (Investor's Business Daily)
01:40PM	Dow Jones, S&P 500 Hit Record Highs Heading Into Christmas Holiday (Investor's Business Daily)
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-25 08:00AM	Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 (Investor's Business Daily)
Nov-10-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31% +5.03%
Nov-06-25 11:00AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Nov-04-25 05:23PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Nov-03-25 01:34AM	Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings (Insider Monkey)
Nov-01-25 02:48PM	Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook (Insider Monkey)
Oct-31-25 07:35PM	Closing Bell Movers: Amazon soars to all-time highs on earnings (TipRanks) +18.58%
04:06PM	Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat (Investor's Business Daily)
11:02PM	Loading…
Oct-30-25 11:02PM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Highlights: Strong FILSPARI Sales and ... (GuruFocus.com)
06:30PM	Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:51PM	Travere: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-29-25 09:41AM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 06:58AM	Chugai acquires Renalys, enhancing its kidney disease portfolio (Pharmaceutical Technology) +6.09%
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-23-25 04:30PM	Travere Therapeutics to Report Third Quarter 2025 Financial Results (Business Wire)
12:22PM	Biotech Leader Travere Therapeutics Eyes Buy Point After More Than Doubling (Investor's Business Daily)
Oct-17-25 09:01AM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Oct-16-25 08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Oct-15-25 12:00PM	What Makes Travere (TVTX) a New Strong Buy Stock (Zacks)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 05:11PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-25 07:00AM	CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy (Business Wire)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 01:16PM	Hims & Hers Leads 14 Growth Stocks Amid Medical Boom (Investor's Business Daily) -6.12%
Sep-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.46%
10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
09:15AM	Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside (Insider Monkey)
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 11:17AM	Stock Market Today: Inflation Data Hits Dow; Oracle Soars As This Biotech Zooms (Live Coverage) (Investor's Business Daily) +26.20%
09:13AM	Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High (Investor's Business Daily)
07:01AM	Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI (sparsentan) in FSGS (Business Wire)
Sep-03-25 07:01AM	Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism (Business Wire) +8.04%
Aug-28-25 10:00AM	Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch (Investor's Business Daily)
Aug-27-25 05:09PM	Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI (sparsentan) in IgA Nephropathy (Business Wire)
Aug-17-25 11:41PM	Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts (Insider Monkey)
Aug-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-25 09:06AM	Travere Therapeutics price target raised to $32 from $30 at Wedbush (TipRanks)
Aug-06-25 06:00PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Travere: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
09:54AM	Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result (GuruFocus.com)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 04:30PM	Travere Therapeutics to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-06-25 04:15AM	Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX) (Insider Monkey)
Jun-24-25 12:46PM	Travere Therapeutics Kicks Off "Play It Forward" Campaign for FSGS Awareness (Insider Monkey) +5.18%
Jun-13-25 02:02PM	HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs (Insider Monkey)
Jun-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:01AM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the 15th International Podocyte Conference (Business Wire)
Jun-10-25 07:00AM	Travere Therapeutics Launches 'Play It Forward' Campaign to Celebrate the FSGS Community on Inaugural Awareness Day (Business Wire)
Jun-03-25 04:30PM	Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress (Business Wire)
May-23-25 04:00AM	England's NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy (PR Newswire)
May-15-25 04:05PM	Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire) -20.57%
May-13-25 04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.59%
May-07-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
May-01-25 11:07PM	Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Travere Therapeutics Reports First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 07:01AM	Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy (Business Wire)
02:00AM	CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy (PR Newswire)
Apr-28-25 10:00AM	Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.62%
Apr-24-25 04:30PM	Travere Therapeutics to Report First Quarter 2025 Financial Results (Business Wire) +5.57%
Apr-12-25 10:20AM	Travere Therapeutics price target lowered to $30 from $32 at Scotiabank (TipRanks)
Apr-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.49%
Apr-07-25 03:27AM	Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-31-25 04:30PM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 (Business Wire) -8.94%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 09:39PM	Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire)
Mar-17-25 07:01AM	Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGS (GlobeNewswire) +5.78%
Mar-12-25 05:30PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.32%

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 04 '26	Sale	32.21	1,779	57,295	105,706	Feb 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	32.19	1,745	56,168	111,226	Feb 05 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 04 '26	Sale	32.18	2,994	96,359	105,211	Feb 05 04:05 PM
ELIZABETH REED	Officer	Feb 04 '26	Proposed Sale	32.18	2,994	96,360		Feb 04 04:07 PM
JULA INRIG	Officer	Feb 04 '26	Proposed Sale	32.21	1,779	57,299		Feb 04 04:06 PM
CHRISTOPHER CLINE	Officer	Feb 04 '26	Proposed Sale	32.19	1,745	56,166		Feb 04 04:01 PM
Peter Heerma	Officer	Feb 03 '26	Proposed Sale	32.12	7,310	234,799		Feb 04 06:00 AM
Elizabeth E. Reed	Officer	Feb 03 '26	Proposed Sale	32.12	7,175	230,464		Feb 03 09:59 PM
Sandra Calvin	Officer	Feb 03 '26	Proposed Sale	32.12	4,333	139,177		Feb 03 09:58 PM
Christopher Cline	Officer	Feb 03 '26	Proposed Sale	32.12	7,242	232,616		Feb 03 09:45 PM
Jula Inrig	Officer	Feb 03 '26	Proposed Sale	32.12	6,956	223,429		Feb 03 09:37 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 03 '26	Sale	32.28	100,087	3,230,316	432,886	Feb 03 09:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 03 '26	Sale	32.12	6,956	223,427	107,485	Feb 03 09:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	32.12	7,242	232,613	112,971	Feb 03 09:30 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 03 '26	Sale	32.12	7,310	234,797	131,823	Feb 03 09:30 PM
ROTE WILLIAM E.	Chief Research Officer	Feb 03 '26	Sale	32.87	12,446	409,100	109,087	Feb 03 09:30 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 03 '26	Sale	32.12	4,333	139,176	49,080	Feb 03 09:30 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 03 '26	Sale	32.12	7,175	230,461	108,205	Feb 03 09:30 PM
Dube Eric M	Officer	Feb 03 '26	Proposed Sale	32.87	100,087	3,289,860		Feb 03 11:38 AM
ROTE WILLIAM E.	Officer	Feb 03 '26	Proposed Sale	32.87	12,446	409,100		Feb 03 10:05 AM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 27 '26	Option Exercise	15.46	51,865	801,833	471,038	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '26	Option Exercise	15.46	8,135	125,767	427,308	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 27 '26	Sale	30.10	51,865	1,560,981	419,173	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '26	Sale	30.01	8,135	244,153	419,173	Jan 27 08:25 PM
Dube Eric M	Officer	Jan 27 '26	Proposed Sale	30.10	51,865	1,560,982		Jan 27 04:05 PM
Dube Eric M	Officer	Jan 23 '26	Proposed Sale	30.01	8,135	244,153		Jan 23 04:14 PM
REED ELIZABETH E	Chief Legal Officer and GC	Jan 20 '26	Option Exercise	19.08	10,000	190,800	100,270	Jan 21 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Jan 20 '26	Sale	27.34	10,000	273,420	90,270	Jan 21 04:05 PM
ELIZABETH REED	Officer	Jan 20 '26	Proposed Sale	27.34	10,000	273,420		Jan 20 04:04 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 05 '26	Sale	40.18	2,031	81,606	86,756	Jan 07 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 06 '26	Sale	37.75	445	16,799	86,311	Jan 07 04:05 PM
JULA INRIG	Officer	Jan 06 '26	Proposed Sale	37.75	445	16,799		Jan 06 04:07 PM
Jula Inrig	Officer	Jan 05 '26	Proposed Sale	40.18	2,031	81,606		Jan 05 07:49 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Dec 24 '25	Sale	40.00	4,980	199,200	113,013	Dec 29 09:11 PM
ROTE WILLIAM E.	Chief Research Officer	Dec 24 '25	Option Exercise	20.61	60,000	1,236,600	161,443	Dec 29 09:05 PM
ROTE WILLIAM E.	Chief Research Officer	Dec 24 '25	Sale	40.10	60,000	2,406,180	101,443	Dec 29 09:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Dec 24 '25	Option Exercise	8.93	15,000	133,950	103,787	Dec 29 09:01 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Dec 24 '25	Sale	42.00	15,000	630,004	88,787	Dec 29 09:01 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 24 '25	Sale	40.00	7,402	296,080	38,233	Dec 29 08:59 PM
JULA INRIG	Officer	Dec 24 '25	Proposed Sale	42.00	15,000	630,004		Dec 29 09:39 AM
SANDRA CALVIN	Officer	Dec 24 '25	Proposed Sale	40.00	7,402	296,080		Dec 29 09:38 AM
Heerma Peter	Officer	Dec 24 '25	Proposed Sale	40.00	4,980	199,200		Dec 29 06:58 AM
ROTE WILLIAM E.	Officer	Dec 24 '25	Proposed Sale	40.10	60,000	2,406,179		Dec 29 06:28 AM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 15 '25	Sale	36.00	2,910	104,760	45,635	Dec 16 04:23 PM
SANDRA CALVIN	Officer	Dec 15 '25	Proposed Sale	36.00	2,910	104,760		Dec 15 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Option Exercise	16.23	20,000	324,600	112,083	Dec 03 04:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Sale	35.01	20,000	700,202	92,083	Dec 03 04:30 PM
CHRISTOPHER CLINE	Officer	Dec 01 '25	Proposed Sale	35.01	20,000	700,200		Dec 01 04:09 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Option Exercise	24.02	61,250	1,471,212	115,660	Nov 06 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Sale	36.00	67,115	2,416,140	48,545	Nov 06 04:05 PM
SANDRA CALVIN	Officer	Nov 04 '25	Proposed Sale	36.00	67,115	2,416,140		Nov 04 04:14 PM
Coughlin Timothy	Director	Oct 31 '25	Option Exercise	16.95	18,000	305,040	73,500	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Sale	35.03	18,000	630,601	55,500	Nov 04 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 31 '25	Sale	35.00	5,591	195,685	119,071	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Proposed Sale	34.98	18,000	629,693		Oct 31 04:05 PM
Heerma Peter	Officer	Oct 31 '25	Proposed Sale	35.00	5,591	195,685		Oct 31 02:51 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Option Exercise	15.46	92,872	1,435,801	512,045	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Option Exercise	15.46	27,128	419,399	446,301	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Sale	30.38	92,872	2,821,358	419,173	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Sale	30.12	27,128	817,074	419,173	Oct 30 04:45 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 28 '25	Sale	30.00	2,662	79,860	124,662	Oct 30 04:45 PM
Dube Eric M	Officer	Oct 29 '25	Proposed Sale	30.12	27,128	817,045		Oct 29 04:26 PM
Dube Eric M	Officer	Oct 28 '25	Proposed Sale	30.38	92,872	2,821,217		Oct 28 04:57 PM
Heerma Peter	Officer	Oct 28 '25	Proposed Sale	30.00	2,662	79,860		Oct 28 02:08 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 22 '25	Option Exercise	19.08	10,000	190,800	99,878	Sep 24 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 22 '25	Sale	25.00	10,000	250,000	89,878	Sep 24 04:05 PM
ELIZABETH REED	Officer	Sep 22 '25	Proposed Sale	25.00	10,000	250,000		Sep 22 04:02 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 03 '25	Sale	18.20	454	8,263	92,202	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 04 '25	Sale	19.71	119	2,345	92,083	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	17.31	470	8,136	92,656	Aug 28 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	14.65	815	11,940	88,787	Jul 02 05:28 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 05 '25	Sale	21.05	1,784	37,553	93,126	May 05 09:54 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 05 '25	Sale	21.05	18,924	398,350	419,173	May 05 09:53 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 05 '25	Sale	21.05	1,771	37,280	128,215	May 05 09:53 PM
ROTE WILLIAM E.	Chief Research Officer	May 05 '25	Sale	21.05	3,198	67,318	100,241	May 05 09:52 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 05 '25	Sale	21.05	4,920	103,566	89,482	May 05 09:51 PM
Christopher Cline	Officer	May 05 '25	Proposed Sale	21.05	1,784	37,553		May 05 07:45 PM
Peter Heerma	Officer	May 05 '25	Proposed Sale	21.05	1,771	37,280		May 05 07:41 PM
REED ELIZABETH E	Officer	May 05 '25	Proposed Sale	21.05	4,920	103,566		May 05 11:32 AM
Dube Eric M	Officer	May 05 '25	Proposed Sale	21.05	18,924	398,350		May 05 11:20 AM
ROTE WILLIAM E.	Officer	May 05 '25	Proposed Sale	21.05	3,198	67,318		May 05 10:08 AM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '25	Sale	13.14	48	631	89,990	Apr 14 06:23 PM
Christopher Cline	Officer	Apr 11 '25	Proposed Sale	13.14	48	631		Apr 11 07:03 PM

Open in Screener

GNSS

Genasys Inc

Feb 11 • 04:00PM ET

1.99

-0.06 -2.93 %

Technology • Scientific & Technical Instruments • USA • NASD

Peers: LMT RTX LHX NOC GD BA TDY TXT HII CW

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.33	Insider Own	20.91%	Shs Outstand	45.21M	Perf Week	6.42%
Market Cap	89.97M	Forward P/E	13.72	EPS next Y	0.14	Insider Trans	0.00%	Shs Float	35.74M	Perf Month	-15.68%
Enterprise Value	96.54M	PEG	-	EPS next Q	-0.01	Inst Own	68.20%	Short Float	2.41%	Perf Quarter	-16.39%
Income	-14.85M	P/S	1.77	EPS this Y	113.47%	Inst Trans	17.20%	Short Ratio	5.47	Perf Half Y	28.39%
Sales	50.88M	P/B	49.82	EPS next Y	222.22%	ROA	-24.29%	Short Interest	0.86M	Perf YTD	-7.23%
Book/sh	0.04	P/C	8.72	EPS next 5Y	-	ROE	-191.92%	52W High	3.73 -46.65%	Perf Year	-31.62%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	3.27% -	ROIC	-398.36%	52W Low	1.46 36.30%	Perf 3Y	-43.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.97% -1.07%	Gross Margin	43.16%	Volatility	6.73% 6.12%	Perf 5Y	-73.54%
Dividend TTM	-	EV/Sales	1.90	EPS Y/Y TTM	49.55%	Oper. Margin	-21.76%	ATR (14)	0.12	Perf 10Y	35.34%
Dividend Ex-Date	Jun 13, 2016	Quick Ratio	0.48	Sales Y/Y TTM	91.38%	Profit Margin	-29.19%	RSI (14)	45.53	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.73	EPS Q/Q	80.07%	SMA20	-2.74%	Beta	0.64	Target Price	4.88
Payout	-	Debt/Eq	9.33	Sales Q/Q	145.89%	SMA50	-7.18%	Rel Volume	1.66	Prev Close	2.05
Employees	187	LT Debt/Eq	1.06	Earnings	Feb 10 AMC	SMA200	-1.58%	Avg Volume	157.42K	Price	1.99
IPO	May 09, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	96.00% 3.42%	Trades		Volume	260,621	Change	-2.93%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-16-21	Initiated	Stephens	Overweight	$8

Feb-11-26 12:02AM	Genasys Inc (GNSS) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... (GuruFocus.com)
Feb-10-26 06:19PM	Genasys Q1 Earnings Call Highlights (MarketBeat)
05:40PM	Genasys (GNSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:39PM	Genasys: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Genasys Reports Fiscal First Quarter 2026 Results (Business Wire)
09:00AM	Loading…
Jan-27-26 09:00AM	Genasys Inc. Schedules Fiscal First Quarter 2026 Financial Results and Conference Call for February 10, 2026 (Business Wire)
Jan-13-26 09:00AM	Genasys, Inc. Provides Third Update on Puerto Rico Dams Early Warning System Project (Business Wire)
Dec-10-25 09:00AM	Genasys Inc. Announces Richard Osgood III to Move to Strategic Advisory Board (Business Wire) -10.25%
12:00AM	Genasys Inc (GNSS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Progress (GuruFocus.com)
Dec-09-25 05:20PM	Genasys (GNSS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:27PM	Genasys: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Genasys Reports Fourth Quarter and Fiscal Year 2025 Results (Business Wire)
Dec-01-25 11:19AM	Zacks Industry Outlook Highlights Ondas and Genasys (Zacks)
Nov-28-25 11:45AM	2 Network Software Stocks to Watch From a Challenging Industry (Zacks)
Nov-20-25 09:00AM	Genasys Inc. Announces $1M Nuclear Security Order (Business Wire)
08:30AM	Loading…
Nov-18-25 08:30AM	Genasys Inc. Appoints Gateway to Lead Expanded Investor Relations Program (Business Wire) -5.75%
Nov-13-25 09:25AM	Ondas Holdings Inc. (ONDS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
09:00AM	Genasys Inc. Schedules Fiscal Year 2025 Financial Results and Conference Call for December 9, 2025 (Business Wire)
Nov-11-25 09:00AM	Genasys Inc. Enters Strategic Partnership With Law Enforcement and Crisis Communications Leader Julie Parker Communications (Business Wire)
Nov-10-25 05:15PM	The Beachbody Company, Inc. (BODI) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-04-25 09:00AM	Genasys Participating in 14th Annual ROTH Technology Conference (Business Wire)
Oct-15-25 09:00AM	Genasys Inc. to Participate in 2025 Maxim Growth Summit (Business Wire)
Oct-13-25 09:00AM	Genasys Completes Alabama-Coushatta Tribe of Texas ACOUSTICS Installation & Commissioning (Business Wire) +7.14%
Oct-03-25 05:33AM	Genasys Secures $9M US Army Order for LRAD Systems Integration into CROWS II Program (Insider Monkey)
Sep-29-25 04:10PM	Genasys Inc. Receives $9.0M LRAD Systems Order for CROWS - Common Remotely Operated Weapon Stations (Business Wire) -7.82% +9.38%
Sep-17-25 09:00AM	Genasys Announces $1.7M LRAD Order from Asia Pacific Region (Business Wire) +9.61%
Aug-28-25 09:00AM	Genasys Receives $1.1M in LRAD Orders from U.S. Military (Business Wire) +7.57%
Aug-15-25 09:09AM	Genasys, Inc. Provides Second Update on Puerto Rico Dams Early Warning System Project (Business Wire) +12.80%
03:22AM	Genasys Inc (GNSS) Q3 2025 Earnings Call Highlights: Revenue Surge Driven by Puerto Rico Project (GuruFocus.com)
Aug-14-25 05:25PM	Genasys (GNSS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:24PM	Loading…
04:24PM	Genasys: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Genasys Inc. Reports Fiscal Third Quarter 2025 Financial Results (Business Wire)
Aug-12-25 06:10PM	H&R Block (HRB) Q4 Earnings Miss Estimates (Zacks)
Aug-07-25 08:50AM	BARK, Inc. (BARK) Reports Q1 Loss, Beats Revenue Estimates (Zacks)
Aug-05-25 06:30PM	The Beachbody Company, Inc. (BODI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-24-25 09:00AM	Genasys Inc. Schedules Fiscal Third Quarter 2025 Financial Results and Conference Call (Business Wire)
Jul-22-25 09:00AM	Genasys Inc. Announces $1.0M in LRAD by Genasys Orders for Middle East and Africa (Business Wire)
Jun-24-25 04:23PM	U.S. Navy Orders $2.0M in LRAD by Genasys Maritime Communication Systems (Business Wire)
Jun-20-25 09:00AM	Genasys Partners With samdesk to Deliver Real-Time Crisis Intelligence for Faster, More Informed Emergency Response (Business Wire)
Jun-19-25 04:35PM	Genasys Inc. Reports Increasing Demand for CONNECT in Wake of Signalgate (Business Wire)
May-19-25 06:30PM	Genasys Inc. Provides Update on Puerto Rico Dam EWS Project (Business Wire) +5.95%
May-14-25 03:14AM	Genasys Inc (GNSS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges (GuruFocus.com) -8.78%
May-13-25 05:15PM	Genasys (GNSS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Genasys Inc. Reports Fiscal Second Quarter 2025 Financial Results (Business Wire)
04:03PM	Genasys Inc. CFO Dennis Klahn to Retire After 45-Year Accounting & Finance Career (Business Wire)
May-12-25 09:45AM	Genasys Inc (GNSS) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com) -12.08%
May-08-25 09:00AM	Genasys Partners With ShakeAlert® to Enhance Protective Communications Platform With Earthquake Early Warnings (Business Wire) +5.64%
May-07-25 06:35PM	A-Mark Precious Metals (AMRK) Lags Q3 Earnings Estimates (Zacks)
Apr-27-25 05:01PM	Genasys Inc. (GNSS): The Best Prison and Law Enforcement Stock to Buy According to Analysts (Insider Monkey)
Apr-23-25 09:00AM	Genasys Inc. Schedules Fiscal Second Quarter 2025 Financial Results and Conference Call (Business Wire)
Apr-02-25 09:00AM	US Military Places $2.5M in New and Follow-On LRAD by Genasys Communication Systems Orders (Business Wire)
Mar-27-25 09:00AM	Genasys Announces $1.0M in Energy Sector Orders (Business Wire)
07:30AM	The Preventable Signal Controversy in the United States Government (Business Wire)
Mar-06-25 09:00AM	Genasys and FloodMapp Partner to Deliver Dynamic Emergency Management and Flood Preparedness (Business Wire) -7.35%
Feb-16-25 02:51PM	Why Genasys Inc. (GNSS) Is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-12-25 02:11AM	Genasys Inc (GNSS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Progress (GuruFocus.com) +21.31%
Feb-11-25 04:05PM	Genasys Inc. Reports Fiscal First Quarter 2025 Financial Results (Business Wire)
Feb-10-25 07:25AM	Genasys Inc (GNSS) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com) -5.81%
Jan-30-25 08:00AM	Genasys Inc. Schedules Fiscal First Quarter 2025 Financial Results and Conference Call (Business Wire)
Jan-16-25 09:00AM	Genasys Inc. Appoints New Independent Director (Business Wire) +8.24%
Dec-23-24 09:00AM	Genasys Provides Calendar Year End Status Report (Business Wire)
Dec-10-24 02:00AM	Genasys Inc (GNSS) Q4 2024 Earnings Call Highlights: A Mixed Bag of International Rebound and ... (GuruFocus.com) -20.00%
Dec-09-24 04:05PM	Genasys Inc. Reports Fiscal Fourth Quarter and Fiscal Year 2024 Financial Results (Business Wire)
09:00AM	Genasys Announces $3.35M Renewal Agreement for Indian Navy LRAD Systems Maintenance (Business Wire)
Dec-06-24 07:01AM	What to Expect from Genasys Inc (GNSS) Q4 2024 Earnings (GuruFocus.com)
Nov-14-24 08:00AM	Genasys Inc. Schedules Fiscal Year 2024 Financial Results and Conference Call for December 9, 2024 (Business Wire)
Nov-07-24 08:00AM	Los Angeles County Adds Genasys ALERT Emergency Warning and Notification to Genasys EVAC Emergency Management and Planning (GlobeNewswire)
Nov-01-24 06:00AM	Maui Emergency Management Agency Awards Genasys Multi-Year Contract for Emergency Alert and AI-Powered Traffic Management Solutions (GlobeNewswire)
Oct-09-24 05:07PM	Genasys Inc (GNSS) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com) -5.75%
Oct-01-24 08:00AM	New LRAD Systems to Enhance Security at Hoover Dam (GlobeNewswire)
Sep-25-24 09:00AM	Genasys Announces International LRAD Law Enforcement and Defense Orders (GlobeNewswire)
Sep-10-24 09:00AM	Genasys Selected by Oregon to Power Emergency Response Planning and Evacuation Management (GlobeNewswire) +8.25%
Sep-05-24 08:15AM	Genasys Receives ACOUSTICS Order from Alabama-Coushatta Tribe of Texas (GlobeNewswire)
08:00AM	Port of Houston Orders New Genasys Protect Systems (GlobeNewswire)
Aug-19-24 07:01PM	Director Mark Culhane Acquires 50,000 Shares of Genasys Inc (GNSS) (GuruFocus.com)
Aug-07-24 04:43PM	Genasys Inc. Signs Agreement to Deploy Emergency Warning System Across Puerto Rico's Dam Infrastructure (GlobeNewswire) +6.93%
Aug-06-24 04:54PM	Genasys Inc. Reports Fiscal Third Quarter 2024 Financial Results (GlobeNewswire)
Jul-23-24 07:00AM	Genasys Inc. Schedules Fiscal Third Quarter 2024 Financial Results and Conference Call for August 6, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	Punahou School Replacing Campus Warning Sirens with Genasys ACOUSTICS Emergency Notification Systems (GlobeNewswire)
Jul-16-24 07:00AM	LRAD Hardware and CONNECT Software Synergies Surging Genasys' Public Safety Sales (GlobeNewswire)
Jul-11-24 05:13PM	Genasys Completes Board of Directors Reconstitution (GlobeNewswire) +5.65%
08:00AM	Singapore Changi Airport Orders Additional LRAD Systems (GlobeNewswire)
Jul-10-24 08:00AM	Santa Barbara County Selects Genasys for Emergency Response Planning and Evacuation Management (GlobeNewswire)
Jun-26-24 08:00AM	Genasys Awarded LRAD Systems Order from Damen Schelde Naval Shipbuilding B.V. for German Navy F-126 Frigate Project (GlobeNewswire)
Jun-25-24 07:00AM	Genasys Lands $900K in LRAD Defense Orders from Middle East (GlobeNewswire) +7.65%
Jun-06-24 07:00AM	MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies (ACCESSWIRE)
May-30-24 07:36PM	San Diego County Regional Public Safety Agencies Launch Genasys EVAC for Enhanced Emergency Communication (GlobeNewswire)
May-23-24 08:00AM	Genasys to Present at MicroCap Rodeo Conference (GlobeNewswire) -6.56%
May-21-24 04:30PM	Genasys Announces Director Resignation Due to New Employment Requirements (GlobeNewswire) +6.40%
May-15-24 08:30AM	Genasys Receives $2.7 Million U.S. Navy Order for LRAD Maritime Systems (GlobeNewswire)
08:18AM	Genasys Inc. (NASDAQ:GNSS) Q2 2024 Earnings Call Transcript (Insider Monkey)
03:08AM	Genasys Inc (GNSS) Q2 2024 Earnings Call Transcript Highlights: Diving Into Financials and ... (GuruFocus.com)
May-14-24 05:45PM	Genasys (GNSS) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.98%
04:14PM	Genasys Inc. Reports Fiscal Second Quarter 2024 Financial Results (GlobeNewswire)
04:14PM	Genasys Announces Expansion of Its Board of Directors (GlobeNewswire)
04:14PM	Genasys Announces $15 Million Two-Year Term Loan Agreement (GlobeNewswire)
Apr-25-24 08:00AM	Genasys Inc. Schedules Fiscal Second Quarter 2024 Financial Results and Conference Call for May 14, 2024 (GlobeNewswire)
Mar-26-24 08:00AM	Genasys Partners in European Union-Funded Project to Revolutionize Public Warning (GlobeNewswire) +11.42%
Feb-15-24 11:07AM	Genasys Inc. (NASDAQ:GNSS) Q1 2024 Earnings Call Transcript (Insider Monkey)
Feb-13-24 04:45PM	Genasys Inc. Reports Fiscal First Quarter 2024 Financial Results (GlobeNewswire) -9.28%

Genasys, Inc. engages in the provision of critical communications hardware and software solutions and a multi-channel approach to deliver geo-targeted alerts, notifications, instructions, and information before, during, and after public safety threats and critical business events. Its communications platform includes Genasys Emergency Management (GEM) applications, National Emergency Warning Systems (NEWS), and LRAD long-range voice broadcast systems. The firm operates through the following segments: Hardware and Software. The company was founded by Elwood G. Norris in 1980 and is headquartered in San Diego, CA.

LAB

Standard BioTools Inc

TVTX

Travere Therapeutics Inc

GNSS

Genasys Inc

Upgrade your FINVIZ experience